Pharmaceutical News

RSS

Matrix honors EP Vantage with European Mediscience 2011 Commentator of the Year award

EP Vantage, part of EvaluatePharma, was presented with the coveted Commentator of the Year Award at the European Mediscience Awards, sponsored by Matrix, on June 22, 2011.

27 Jun 2011

Vaccination against rotavirus decreases hospitalization rates among infants

[Vaccination against rotavirus, a major cause of severe acute gastroenteritis in children, dramatically decreased hospitalization rates for the infection among infants in three U.S. counties, according to a new study published in Clinical Infectious Diseases and now available online.

27 Jun 2011

Intravenous diclofenac holds promise against severe pain following oral surgery

An essential aspect of oral surgery is controlling the patient's pain following a procedure. The goal is to relieve pain and promote a rapid recovery, without opioid side effects. An initial study shows that Dyloject, a new intravenous form of the drug diclofenac, has promise for achieving these goals.

27 Jun 2011

Some HIV drugs can cause premature ageing

A class of anti-retroviral drugs commonly used to treat HIV, particularly in Africa and low income countries, can cause premature ageing, according to research published today in the journal Nature Genetics. The study shows that the drugs damage DNA in the patient's mitochondria - the 'batteries' which power their cells.

27 Jun 2011

Isotechnika's partner Lux to appeal EMA CHMP decision against Luveniq

Isotechnika Pharma Inc. today announced that its partner, Lux Biosciences, Inc. will appeal the European Medicines Agency's (EMA) decision not to approve Luveniq™ (voclosporin) as a treatment for noninfectious uveitis involving the intermediate or posterior segments of the eye.

24 Jun 2011

EMA approves Shire's new REPLAGAL manufacturing facility in Lexington

Shire plc, the global specialty biopharmaceutical company, today announced that the European Medicines Agency has approved the purification of REPLAGAL® (agalsidase alfa) drug substance at its new manufacturing facility in Lexington, MA, US. REPLAGAL, Shire's enzyme replacement therapy for the treatment of Fabry disease is the first product that will be made available to patients from the new facility.

24 Jun 2011

EMA CHMP recommends approval of linagliptin for type 2 diabetes

Boehringer Ingelheim and Eli Lilly and Company today received a positive opinion from the European Medicines Agency's (EMA) medicinal committee recommending approval of linagliptin, 5 mg, film-coated tablets (to be marketed under the trade name Trajenta® in Europe) for the treatment of adults with type 2 diabetes.

24 Jun 2011

Supreme Court sides with drug makers in two decisions

One would shield pharmaceutical companies from most lawsuits filed by people injured by taking generic drugs. The other strikes down a Vermont law that banned some commercial uses — "data mining" — of prescription data.

24 Jun 2011

Nutrastar opens Harbin specialty store in central Nangang District

Nutrastar International Inc., a leading producer and supplier of premium branded Traditional Chinese Medicine ("TCM") consumer products, today announced the opening of its second branded specialty store in Harbin. The store carries the company's core Cordyceps product and all of the Company's functional health beverage products.

24 Jun 2011

FDA approves second anti-HIV drug from Rutgers-Janssen collaboration

Two decades after Rutgers scientists began working with Paul Janssen, a legendary drug developer and founder of Johnson & Johnson subsidiary Janssen Pharmaceutica, to create new and potent drugs to fight AIDS, the FDA has approved the second anti-HIV drug that came from this collaboration.

24 Jun 2011

FDA approves Lannett's NDA for Morphine Sulfate Oral Solution

Lannett Company, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the company's 505(b)(2) New Drug Application (NDA) for Morphine Sulfate Oral Solution on June 23, 2011.

24 Jun 2011

EMA CHMP issues positive opinion for Baxter's IVIG therapy for multifocal motor neuropathy

Baxter International Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for extension of the therapeutic indications of KIOVIG to include a new indication for multifocal motor neuropathy (MMN), a severe, debilitating disorder requiring lifelong treatment.

From Baxter International Inc. 24 Jun 2011

Unavailability of Avastin more dangerous risk for breast cancer patients, says FAMEDS founder

Breast cancer patients and their families will rally together on Tuesday, June 28, at 7:00 am outside of the Federal Drug Administration (FDA). At issue will be the FDA's final hearing to remove the anti-cancer drug Avastin from the approved medication list for treatment of late stage breast cancer, despite the FDA approving it in 2008 for use to treat breast cancer.

24 Jun 2011

Pfizer and Pain Therapeutics receive FDA Complete Response Letter for resubmission of REMOXY NDA

Pfizer and Pain Therapeutics, Inc. announced that a Complete Response Letter was received from the U.S. Food and Drug Administration (FDA) on the resubmission to the new drug application (NDA) for REMOXY® (oxycodone) Extended-Release Capsules CII. Pfizer is working to evaluate the issues described in the Complete Response Letter and plans to have further discussions with FDA around them.

24 Jun 2011

Automated screening system helps identify cases of unexpected drug diversions

Electronic data from automated drug dispensing carts can help to identify drug diversion by anesthesia care providers, according to a report in the July issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

24 Jun 2011

ViroPharma receives positive European CHMP opinion for Buccolam to treat acute seizures

ViroPharma Incorporated today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of a Pediatric Use Marketing Authorization (PUMA) for Buccolam, for treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents, from 3 months to less than 18 years.

24 Jun 2011

Cocaine contaminated with livestock de-worming drug causes painful purpura

If the obvious reasons for avoiding recreational drug use aren't off-putting enough, physicians have yet another detrimental consequence to add to the list - crusty, purplish areas of dead skin that are extremely painful and can open the door to nasty infections.

24 Jun 2011

Scientists develop new NO delivery system to fortify effects of Viagra in the body

Scientists are reporting development and successful initial tests of a potential new delivery system for the biological signaling agent responsible for the effects of Viagra.

24 Jun 2011

Endo's complete response for new formulation of OPANA ER NDA accepted by the FDA

Endo Pharmaceuticals announced today that it received notification from the U.S. Food and Drug Administration (FDA) that Endo's complete response to the FDA's Jan. 7, 2011 Action Letter relating to Endo's new drug application (NDA) for a new formulation of OPANA ER has been accepted.

24 Jun 2011

$Inhaled corticosteroids linked to increased risk of fractures in patients with COPD$

Inhaled corticosteroids linked to increased risk of fractures in patients with COPD

Patients with chronic obstructive pulmonary disease (COPD) who use inhaled corticosteroids to improve breathing for more than six months have a 27 percent increased risk of bone fractures, new Johns Hopkins-led research suggests.

24 Jun 2011

Pharmaceutical News

Matrix honors EP Vantage with European Mediscience 2011 Commentator of the Year award

Vaccination against rotavirus decreases hospitalization rates among infants

Intravenous diclofenac holds promise against severe pain following oral surgery

Some HIV drugs can cause premature ageing

Isotechnika's partner Lux to appeal EMA CHMP decision against Luveniq

EMA approves Shire's new REPLAGAL manufacturing facility in Lexington

EMA CHMP recommends approval of linagliptin for type 2 diabetes

Supreme Court sides with drug makers in two decisions

Nutrastar opens Harbin specialty store in central Nangang District

FDA approves second anti-HIV drug from Rutgers-Janssen collaboration

FDA approves Lannett's NDA for Morphine Sulfate Oral Solution

EMA CHMP issues positive opinion for Baxter's IVIG therapy for multifocal motor neuropathy

Unavailability of Avastin more dangerous risk for breast cancer patients, says FAMEDS founder

Pfizer and Pain Therapeutics receive FDA Complete Response Letter for resubmission of REMOXY NDA

Automated screening system helps identify cases of unexpected drug diversions

ViroPharma receives positive European CHMP opinion for Buccolam to treat acute seizures

Cocaine contaminated with livestock de-worming drug causes painful purpura

Scientists develop new NO delivery system to fortify effects of Viagra in the body

Endo's complete response for new formulation of OPANA ER NDA accepted by the FDA

Inhaled corticosteroids linked to increased risk of fractures in patients with COPD

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News